Immunoglobulin light chain amyloidosis: new therapy and biomarkers / 中国医师进修杂志

ABSTRACT

Amyloidosis is a systemic disease whose clinical manifestations and pathological changes are caused by the deposition of amyloid substances in different organs of the body.Kidney is one of the most frequently affected organs of amyloidosis.Amyloid protein should be genotyped in time, with the aim of identifying the precursor protein and identifying the corresponding type of amyloidosis.The use of biomarkers can help identify amyloid precursor, assess the presence and severity of organ involvement, and monitor the response to treatment. In recent years, the serum free light chain (FLCs) can be a biomarker of immunoglobulin light chain amyloidosis, targeting plasma cell antigen CD38(daratumumab) and humanized 2A4 monoclonal antibody NEOD001 is promising for immunoglobulin light chain amyloidosis to be an effective therapeutic agent.